Cheryl Guttman Krader, BS, Pharm



Treat-and-extend protocol reduces burden of anti-VEGF treatment for DME

January 17, 2018

Results of the prospective TREX-DME study provide an evidence base for using a treat-and-extend protocol for administering anti-VEGF injections for eyes with diabetic macular edema.

Suprachoroidal corticosteroid shows visual, anatomic improvements in DME eyes

January 11, 2018

Suprachoroidal triamcinolone acetonide (CLS-TA, Clearside Biomedical) injection resulted in visual and anatomic improvements in eyes with diabetic macular edema, particularly in those that were treatment-naïve. Multiple injections of the investigational treatment were well-tolerated and associated with a low incidence of IOP elevation.

VMA associated with poor outcomes in anti-VEGF-treated patients

July 20, 2017

The presence of vitreomacular adhesion (VMA) is associated with poorer, short-term anatomic, and functional outcomes in eyes with diabetic macular edema (DME) receiving anti-VEGF therapy, according to Márcio B. Nehemy, MD, PhD.